Lynda Dzubinski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lynda Dzubinski has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Robert E. Schoen
Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, USA
154 shared publications - Aatur D. Singhi
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
94 shared publications - Ajay Bansal
Department of Gastroenterology, University of Kansas Medical Center, and University of Kansas Cancer Center, United States
94 shared publications - Andres Salazar
Oncovir 17 , Washington, District of Columbia
94 shared publications - Asad Umar
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
94 shared publications - Brenda Diergaarde
Department of Human Genetics, School of Public Health University of Pittsburgh Pittsburgh Pennsylvania USA
94 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 2: Summary patient characteristics for Comparison Set 1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 2: Summary patient characteristics for Comparison Set 1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 3: EVL methylation levels of normal colon for patients with no history of adenoma or cancer after initial colonoscopy (left group) and for levels patients with an adenoma or colorectal cancer detected after initial (middle group). Patients with no follow-up colonoscopies (right group) were not included in the analyses for Comparison Set 2. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 3: EVL methylation levels of normal colon for patients with no history of adenoma or cancer after initial colonoscopy (left group) and for levels patients with an adenoma or colorectal cancer detected after initial (middle group). Patients with no follow-up colonoscopies (right group) were not included in the analyses for Comparison Set 2. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 1. Flowchart of patient selection. * Subjects with hereditary conditions or inflammatory bowel disease (IBD) were excluded. A flowchart showing the selection process for the subjects included in the studies is shown. The primary exclusion criteria that affected subject selection were lack of serial colonoscopy data and lack of tissue from the normal colon
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 1. Flowchart of patient selection. * Subjects with hereditary conditions or inflammatory bowel disease (IBD) were excluded. A flowchart showing the selection process for the subjects included in the studies is shown. The primary exclusion criteria that affected subject selection were lack of serial colonoscopy data and lack of tissue from the normal colon
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 2: Methylation levels of normal colon mucosa in patients with no history of adenoma or cancer ever (group on left) and levels for patients with a history of adenoma(s) or colorectal cancer at initial or a follow-up colonoscopy (group on right) in Comparison Set 1. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 2: Methylation levels of normal colon mucosa in patients with no history of adenoma or cancer ever (group on left) and levels for patients with a history of adenoma(s) or colorectal cancer at initial or a follow-up colonoscopy (group on right) in Comparison Set 1. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 7: Summary statistics for methylated EVL measurements in Comparison Set 3
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 7: Summary statistics for methylated EVL measurements in Comparison Set 3
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 5: Summary statistics for methylated EVL measurements in Comparison Set 1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 5: Summary statistics for methylated EVL measurements in Comparison Set 1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 4: Summary patient characteristics for Comparison Set 3
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 4: Summary patient characteristics for Comparison Set 3
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 1: Primer/probe sequences used in the duplex mEVL assay
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 1: Primer/probe sequences used in the duplex mEVL assay
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 4: Methylation levels of normal colon for patients with no history of adenoma or cancer after initial amongst those at least 4 years of follow-up (left group) and levels for patients with an adenoma or colorectal cancer detected after initial colonoscopy (middle group). Patients without an adenoma or colorectal cancer and less than 4 years of follow-up (right group) were not included in the analyses for Comparison Set 3. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 4: Methylation levels of normal colon for patients with no history of adenoma or cancer after initial amongst those at least 4 years of follow-up (left group) and levels for patients with an adenoma or colorectal cancer detected after initial colonoscopy (middle group). Patients without an adenoma or colorectal cancer and less than 4 years of follow-up (right group) were not included in the analyses for Comparison Set 3. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 6: Summary statistics for methylated EVL measurements in Comparison Set 2
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 6: Summary statistics for methylated EVL measurements in Comparison Set 2